US Stock MarketDetailed Quotes

OCGN Ocugen

Watchlist
  • 0.7995
  • +0.0756+10.44%
Close Mar 28 16:00 ET
  • 0.7988
  • -0.0007-0.09%
Post 20:01 ET
233.47MMarket Cap-4.00P/E (TTM)

About Ocugen Company

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Company Profile

SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees95
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Shankar Musunuri, M.B.A.,PhD
  • Chairman of the Board and Chief Executive Officer
  • --
  • Arun Upadhyay, PhD
  • Chief Scientific Officer and Head, Research, Development, and Medical
  • --
  • Dr. Huma Qamar, M.D.,PhD
  • Chief Medical Officer
  • --
  • Ramesh Ramachandran
  • Principal Financial Officer and Chief Accounting Officer
  • --
  • Kirsten Castillo, M.B.A.
  • Independent Director
  • --
  • Uday B. Kompella, PhD
  • Independent Director
  • --
  • Dr. Prabhavathi Fernandes, PhD
  • Lead Independent Director
  • --
  • Dr. Marna C. Whittington, PhD
  • Independent Director
  • --
  • Dr. Junge Zhang, PhD
  • Independent Director
  • --
  • Michael Breininger, C.P.A.,M.B.A.
  • Corporate Controller
  • --

Market Insights

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More